CompletedPhase 2NCT00298233
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Studying Avian influenza
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Tawee Chotpitayasunohdh, MDQueen Sirikit National Institute of Child Health, Bangkok, Thailand
- Intervention
- Oseltamivir(drug)
- Enrollment
- 326 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2006 – 2010
Study locations (12)
- Changi General Hospital, Singapore, Singapore
- National University Hospital, National University of Singapore, Singapore, Singapore
- Tan Tock Seng Hospital, Singapore, Singapore
- Queen Sirikit National Institute of Child Health, Bangkok, Thailand
- Siriraj Hospital Mahidol University, Bangkok, Thailand
- Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand
- Chest Disease Institute, Nonthaburi, Thailand
- National Hospital of Pediatrics, Hanoi, Vietnam
- National Institute fof Infectious and Tropical Diseases, Hanoi, Vietnam
- Children's Hospital #1, Ho Chi Minh City, Vietnam
- Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- Pediatric Hospital #2, Ho Chi Minh City, Vietnam
Collaborators
Wellcome Trust · World Health Organization · University of Oxford
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00298233 on ClinicalTrials.govOther trials for Avian influenza
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc.
- RECRUITINGPHASE3NCT07240558Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)University Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE4NCT07275060Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartCanadian Immunization Research Network
- RECRUITINGPHASE1, PHASE2NCT06842173Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsButantan Institute
- ACTIVE NOT RECRUITINGPHASE1NCT07019883A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT06850298H5N1 Milk Detection StudyEmory University